Dermata Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Balance Sheet Details (Tables)

12 Months Ended

Dec. 31, 2022

	As of December 31,
	2022		2021

Prepaid expenses and other current assets
Prepaid insurance	$	586,407	$	769,416
Prepaid research and development costs		92,581		-
Prepaid other		11,604
Interest receivable		12,602
Deferred offering costs		-		55,718
Total prepaid expenses and other current assets	$	703,194	$	825,134

Accrued and other current liabilities
Accrued research and development costs	$	254,787	$	235,384
Accrued compensation and benefits		170,389		766,207
Accrued other		756
Total accrued and other current liabilities	$	425,932	$	1,001,591